Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2004-002102-30-IT
EUCTR2004-002102-30-ITActive, not recruitingNot Applicable

OPEN-LABEL, SINGLE-ARM STUDY OF THE SAFETY AND EFFICACY OF CC-5013 MONOTHERAPY FOR SUBJECTS WITH MULTIPLE MYELOMA A COMPANION STUDY FOR STUDIES THAL-MM-003, CC-5013-MM-009, AND CC-5013-MM-010

CELGENE EUROPE LIMITED0 sites738 target enrollmentStarted: February 8, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
738
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Active, not recruiting
Phase 1
AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISAtopic dermatitis
EUCTR2019-004301-28-PLDermira, Inc., a wholly owned subsidiary of Eli Lilly and Company200
Active, not recruiting
Phase 1
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864
EUCTR2013-001790-25-DEForesee Pharmaceuticals Co., Ltd.137
Active, not recruiting
Phase 1
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864
EUCTR2013-001790-25-SKForesee Pharmaceuticals Co., Ltd.133
Active, not recruiting
Phase 1
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864
EUCTR2013-001790-25-LTForesee Pharmaceuticals Co., Ltd.133
Active, not recruiting
Phase 1
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864
EUCTR2013-001790-25-ATForesee Pharmaceuticals Co., Ltd.133
OPEN-LABEL, SINGLE-ARM STUDY OF THE SAFETY... | Clinical Trial